Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Graefen

Showing results (71-80 of 917) with videos related to

Pageof 92
Sort By:
European Urology|February 27, 2021
Re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.040: Time for a Change? Clinically Meaningful Reasons Why We Will Continue Performing Extended Pelvic Lymph Node Dissection in Selected Patients with Prostate CancerAlberto Briganti, Giorgio Gandaglia, Markus Graefen, et al.
European Urology|October 26, 2011
Does low-risk prostate cancer detection change with repeat biopsies?Bobby B Najari, Michael Rink, Markus Graefen, et al.
Cancer|January 10, 2006
Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomyThomas Steuber, Andreas Erbersdobler, Markus Graefen, et al.
Frontiers in Surgery|February 22, 2021
Impact of Sarcopenia on Functional and Oncological Outcomes After Radical ProstatectomyMarkus Angerer, Georg Salomon, Dirk Beyersdorff, et al.
European Urology|January 22, 2005
Influence of nerve-sparing (NS) procedure during radical prostatectomy (RP) on margin status and biochemical failureRein-Jüri Palisaar, Joachim Noldus, Markus Graefen, et al.
The Oncologist|September 28, 2012
A comment on the International Society of Geriatric Oncology guidelines: evidence-based advice for the clinical settingJohn M Fitzpatrick, Markus Graefen, Heather A Payne, et al.
European Urology Focus|February 9, 2020
The Significance of Primary Biopsy Gleason 5 in Patients with Grade Group 5 Prostate CancerDerya Tilki, Christoph Würnschimmel, Felix Preisser, et al.
European Urology Open Science|November 17, 2021
Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer RecurrenceSophie Knipper, Sabine Riethdorf, Stefan Werner, et al.
Deutsches Arzteblatt International|February 7, 2021
Options for Curative Treatment of Localized Prostate CancerSophie Knipper, Saskia Ott, Heinz-Peter Schlemmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2022
Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of DeathDerya Tilki, Ming-Hui Chen, Jing Wu, et al.
Pageof 92

Showing results (71-80 of 917) with videos related to

Sort By:
Pageof 92
European Urology|February 27, 2021
Re: Jean F.P. Lestingi, Giuliano B. Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.040: Time for a Change? Clinically Meaningful Reasons Why We Will Continue Performing Extended Pelvic Lymph Node Dissection in Selected Patients with Prostate CancerAlberto Briganti, Giorgio Gandaglia, Markus Graefen, et al.
European Urology|October 26, 2011
Does low-risk prostate cancer detection change with repeat biopsies?Bobby B Najari, Michael Rink, Markus Graefen, et al.
Cancer|January 10, 2006
Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomyThomas Steuber, Andreas Erbersdobler, Markus Graefen, et al.
Frontiers in Surgery|February 22, 2021
Impact of Sarcopenia on Functional and Oncological Outcomes After Radical ProstatectomyMarkus Angerer, Georg Salomon, Dirk Beyersdorff, et al.
European Urology|January 22, 2005
Influence of nerve-sparing (NS) procedure during radical prostatectomy (RP) on margin status and biochemical failureRein-Jüri Palisaar, Joachim Noldus, Markus Graefen, et al.
The Oncologist|September 28, 2012
A comment on the International Society of Geriatric Oncology guidelines: evidence-based advice for the clinical settingJohn M Fitzpatrick, Markus Graefen, Heather A Payne, et al.
European Urology Focus|February 9, 2020
The Significance of Primary Biopsy Gleason 5 in Patients with Grade Group 5 Prostate CancerDerya Tilki, Christoph Würnschimmel, Felix Preisser, et al.
European Urology Open Science|November 17, 2021
Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer RecurrenceSophie Knipper, Sabine Riethdorf, Stefan Werner, et al.
Deutsches Arzteblatt International|February 7, 2021
Options for Curative Treatment of Localized Prostate CancerSophie Knipper, Saskia Ott, Heinz-Peter Schlemmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2022
Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of DeathDerya Tilki, Ming-Hui Chen, Jing Wu, et al.
Pageof 92